查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1458405

全球血浆分馏市场：依产品类型、方法、应用、最终用户、地区、机会、预测，2017-2031 年

Plasma Fractionation Market Assessment, By Product Type, By Method, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 239 Pages | 商品交期: 3-5个工作天内

价格

2024-2031年预测期间，全球血浆分离市场规模将以7.28%的复合年增长率扩大，从2023年的302.5亿美元增长到2031年的530.5亿美元。 血浆分离市场受到血浆治疗需求增加、分离技术进步以及患有血液相关疾病的老龄化人口中目标疾病发病率增加等因素的影响越来越大。 血浆分离在从人类血浆生产基本治疗药物和满足各种医疗需求方面发挥重要作用。 血浆疗法的日益普及以及血浆产品在各种治疗方式和工业应用中的使用显着增加了对血浆分离市场的需求。 此外，投资者开拓市场并获利的运动也进一步支撑了市场的成长。 然而，血浆分离市场的主要限制包括高成本和有限的报销，以及重组替代品对市场的干扰。 此外，严格的监管要求可能会使新公司进入市场以及现有公司将新产品推向市场变得困难。

随着罕见疾病的增加以及对血浆衍生治疗的依赖，血浆疗法越来越受到追捧，这种需求正在推动全球市场的成长。 泛美卫生组织等组织提倡定期自愿捐血和血浆，以维持可靠的供应，特别是在捐血不足的地区。 然而，COVID-19 大流行减少了血浆捐赠，导致血浆治疗的基本材料短缺。 随着对血浆治疗和血浆产品的需求不断增加，血浆分离解决方案的市场预计在未来几年将显着增长。

本报告调查了全球血浆分离市场，并依产品类型、方法、应用、最终用户、地区以及参与该市场的公司概况提供了市场概况、趋势。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章 2017-2031 年全球血浆分馏市场展望

  • 市场规模与预测
  • 依产品类型
  • 依方法
  • 依用途
  • 依最终用户
  • 依地区
  • 各公司的市占率 (%)，2023 年

第 5 章 2017-2031 年全球血浆分馏市场前景（依地区）

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章 2023 年市场规划

第七章宏观环境与产业结构

  • 需求与供给分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

第 9 章监理架构与创新

第十章主要参会企业状况

第11章价格分析

第 12 章案例研究

第 13 章主要进入者展望

  • Grifols S.A.
  • CSL Limited Takeda Pharmaceutical Company Limited Octapharma AG Kedrion S.p.A LFB S.A. Biotest AG Sanquin Innovation B.V. Bio Products Laboratory Ltd. Intas Pharmaceuticals Ltd

第 14 章策略建议

第十五章查询及免责声明

Product Code: MX11202

Global plasma fractionation market is projected to witness a CAGR of 7.28% during the forecast period 2024-2031, growing from USD 30.25 billion in 2023 to USD 53.05 billion in 2031. The plasma fractionation market is thriving under the influence of factors, including the rising demand for blood plasma therapies, advancements in fractionation technologies, and the growing occurrence of target diseases among an aging population with blood-related diseases. Plasma fractionation plays a crucial role in producing essential therapeutics from human plasma, addressing various medical needs. The growing adoption of plasma therapies and utilization of plasma products in various therapeutics and industrial applications significantly increases the demand in the plasma fractionation market. Alongside, the investors' traction to develop the market and derive profit out of it, further enhances the market growth. However, the main restraints for the plasma fractionation market include high costs and limited reimbursements, as well as market disruption caused by recombinant alternatives. Additionally, stringent regulatory requirements can make it difficult for new companies to enter the market and for existing companies to bring new products to market.

In November 2023, Grifols, a respected plasma medicine company, gained FDA approval for its expanded manufacturing site in Clayton. This approval covers the production of Gamunex-C, a prominent Grifols immunoglobulin (Ig) brand. With the new facility, Grifols can now produce 16 million grams of Gamunex-C annually, boosting its global capacity to 60 million grams. Grifols is also planning to secure FDA approval to produce XEMBIFY, its rapidly growing subcutaneous Ig, at the same facility.

Rising Demand for Blood Plasma Therapies

Plasma therapy is becoming increasingly sought-after due to the growing number of rare diseases and reliance on treatments derived from blood plasma. This demand is boosting market growth worldwide. Organizations like PAHO advocate for regular and voluntary blood and plasma donations to maintain a reliable supply, particularly in areas where donations are insufficient. However, the COVID-19 pandemic reduced plasma donations, resulting in a shortage of essential materials for plasma-based treatments. With the increasing demand for plasma therapies and plasma products, the market for plasma fractionation solutions is anticipated to rise significantly in the upcoming future. Manufacturers like Takeda are dedicated to developing manufacturing setups to cater to the growing requirements of the market.

In April 2023, Takeda, a leading Japanese biopharmaceutical company, plans to construct Japan's largest facility for producing plasma-based medicines (PDTs) in Osaka. This investment aims to meet the growing demand for PDTs domestically and globally. The new facility will significantly increase Takeda's plasma manufacturing capacity in Japan by approximately five times. With an estimated investment of JPY 100 billion, construction will commence in early 2024, and the facility is expected to be operational by 2030, bolstering Takeda's global manufacturing network.

Growing Prevalence of Immunodeficiency Diseases

The growing prevalence of immunodeficiency diseases is driving the demand for plasma fractionation due to the effectiveness of plasma-derived therapies in treating these conditions. Plasma-derived therapies have become essential treatment options for rare diseases and immunodeficiency disorders, leading to a surge in demand for these therapies. Plasma fractionation involves separating and purifying key blood plasma components like immunoglobulins, albumins, and anticoagulant factors, which are crucial for formulating life-saving therapeutics. Primary immunodeficiency diseases affect an estimated 60 lakh people worldwide, and 70% to 90% of individuals have undiagnosed primary immunodeficiency conditions. As per an estimation, about 5,000 individuals within the United Kingdom suffer from primary immunodeficiency disorder. Approximately 50.5 people out of every 1,00,000 in the United States are estimated to have a primary immunodeficiency disorder.

Immunoglobulins Segment to be Fastest Growing

Immunoglobulins are popular for plasma fractionation due to their use in treating individuals with antibody deficiencies. Immunoglobulin replacement therapy is the standard treatment for these patients, and it involves the administration of intravenous immunoglobulin (IVIG) or subcutaneously (SCIG). Immunoglobulin is used to help patients suffering from primary and secondary immunodeficiency disorders and combat viral and bacterial infections. Several products related to this segment are under clinical investigation and seem to grow with time. For instance, in July 2023, the FDA approved the updated application for GC5107B, an immune globulin solution intended for intravenous use in patients who have a weakened immune system known as primary humoral immunodeficiency. This liquid solution contains human immunoglobulin G (100mg/mL) and is extracted from donated human plasma in the United States. The application is supported by a study that observed the effectiveness and safety of GC5107B with 49 patients between the ages of 3 and 70 with confirmed primary immunodeficiency.

Centrifugation to be Leading Method Type

Centrifugation is a widely used method for plasma fractionation due to its effectiveness in separating individual plasma proteins based on their density. The process involves using centrifuges and centrifugal force to segregate plasma proteins, with precipitated proteins of higher density remaining in the centrifuge, while lighter components are forced out. This method has seen increased application over the years, leading to the development of specialized centrifuges for large-scale plasma processing. In industrial settings, vertical centrifuge plasma fractionation systems are designed specifically for pharmaceutical applications to separate different plasma fractions efficiently. These systems ensure optimal yield of valuable raw materials with maximum purity and quality, meeting the stringent requirements of reliable processes in medical applications.

North America to be the Dominating Region

North America's leadership in the plasma fractionation market stems from several key reasons. Most plasma supplies for manufacturing plasma-derived medicinal products come from North American countries, with the United States commercial plasma industry historically dominating international supply. The United States plays a crucial role in meeting international needs for plasma due to its significant export of plasma-derived products. The United States supplies around 70% of the world's plasma. The strong presence of market players in North America strengthens the lead of the region in plasma fractionation market. In April 2023, CSL Plasma, a subsidiary of CSL Behring, opened a new plasma collection center in Kankakee, Illinois. This marks their 320th center in the U.S. Located near the CSL Behring manufacturing site, this center collects plasma used to create life-saving therapies for rare and severe diseases, such as immune disorders, swelling, respiratory diseases, and bleeding or neurological conditions.

Future Market Scenario (2024 - 2031F)

Future trends in plasma-derived therapies include a focus on reducing fractionation scale, adopting new technologies, and increasing automation to improve efficiency and reduce costs. The plasma industry is exploring novel manufacturing technologies, such as flammable material-free fractionation and continuous manufacturing, to improve the efficiency of fractionation facilities. Additionally, there is a growing demand for plasma-derived therapies due to an aging population, clinical successes, and recent applications for both widespread diseases and many rare conditions. Apart from this, an increase in the number of plasma collection centers is also strengthening the plasma fractionation market. For instance, in November 2023, ADMA Biologics, a biopharmaceutical company specializing in plasma-derived biologics, has secured FDA approval for its newest plasma collection center in Laurel, Maryland. This facility began operations earlier this year and has already started collecting plasma. With this approval, ADMA can now distribute the collected plasma in the U.S. for further processing into biological products.

Key Players Landscape and Outlook

Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Biotest AG, Sanquin Innovation B.V., and Bio Products Laboratory Ltd. are some of the key players in the plasma fractionation market. These companies are actively involved in research and development initiatives to launch new plasma-derived therapies and are focusing on acquiring new plasma collection centers to streamline their operations, along with expanding their manufacturing facilities.

In December 2023, GC Biopharma, a South Korean biotech firm, commenced construction on a plasma fractionation plant in Indonesia's Jababeka Industrial Estate. This plant will be the first of its kind in the country. The project was approved by the Indonesian government in June, and construction is underway after just six months of progress. The project is supported by the government's commitment to advancing healthcare.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Plasma Fractionation Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Product Type
    • 4.2.1.Albumin
    • 4.2.2.Immunoglobulins
      • 4.2.2.1.Intravenous immunoglobulins
      • 4.2.2.2.Subcutaneous immunoglobulins
      • 4.2.2.3.Others
    • 4.2.3.Coagulation Factors
      • 4.2.3.1.Factor VIII
      • 4.2.3.2.Factor IX
      • 4.2.3.3.Von Willebrand Factor
      • 4.2.3.4.Prothrombin Complex Concentrates
      • 4.2.3.5.Fibrinogen Concentrates
      • 4.2.3.6.Others
    • 4.2.4.Protease Inhibitors
    • 4.2.5.Others
  • 4.3.By Method
    • 4.3.1.Centrifugation
    • 4.3.2.Depth Filtration
    • 4.3.3.Chromatography
    • 4.3.4.Others
  • 4.4.By Application
    • 4.4.1.Neurology
    • 4.4.2.Hematology
    • 4.4.3.Oncology
    • 4.4.4.Immunology
    • 4.4.5.Pulmonology
    • 4.4.6.Others
  • 4.5.By End-user
    • 4.5.1.Hospitals & Clinics
    • 4.5.2.Clinical Research
    • 4.5.3.Others
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global Plasma Fractionation Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Product Type
      • 5.1.2.1.Albumin
      • 5.1.2.2.Immunoglobulins
      • 5.1.2.2.1.Intravenous immunoglobulins
      • 5.1.2.2.2.Subcutaneous immunoglobulins
      • 5.1.2.2.3.Others
      • 5.1.2.3.Coagulation Factors
      • 5.1.2.3.1.Factor VIII
      • 5.1.2.3.2.Factor IX
      • 5.1.2.3.3.Von Willebrand Factor
      • 5.1.2.3.4.Prothrombin Complex Concentrates
      • 5.1.2.3.5.Fibrinogen Concentrates
      • 5.1.2.3.6.Others
      • 5.1.2.4.Protease Inhibitors
      • 5.1.2.5.Others
    • 5.1.3.By Method
      • 5.1.3.1.Centrifugation
      • 5.1.3.2.Depth Filtration
      • 5.1.3.3.Chromatography
      • 5.1.3.4.Others
    • 5.1.4.By Application
      • 5.1.4.1.Neurology
      • 5.1.4.2.Hematology
      • 5.1.4.3.Oncology
      • 5.1.4.4.Immunology
      • 5.1.4.5.Pulmonology
      • 5.1.4.6.Others
    • 5.1.5.By End-user
      • 5.1.5.1.Hospitals & Clinics
      • 5.1.5.2.Clinical Research
      • 5.1.5.3.Others
    • 5.1.6.United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Product Type
      • 5.1.6.2.1.Albumin
      • 5.1.6.2.2.Immunoglobulins
      • 5.1.6.2.2.1.Intravenous immunoglobulins
      • 5.1.6.2.2.2.Subcutaneous immunoglobulins
      • 5.1.6.2.2.3.Others
      • 5.1.6.2.3.Coagulation Factors
      • 5.1.6.2.3.1.Factor VIII
      • 5.1.6.2.3.2.Factor IX
      • 5.1.6.2.3.3.Von Willebrand Factor
      • 5.1.6.2.3.4.Prothrombin Complex Concentrates
      • 5.1.6.2.3.5.Fibrinogen Concentrates
      • 5.1.6.2.3.6.Others
      • 5.1.6.2.4.Protease Inhibitors
      • 5.1.6.2.5.Others
      • 5.1.6.3.By Method
      • 5.1.6.3.1.Centrifugation
      • 5.1.6.3.2.Depth Filtration
      • 5.1.6.3.3.Chromatography
      • 5.1.6.3.4.Others
      • 5.1.6.4.By Application
      • 5.1.6.4.1.Neurology
      • 5.1.6.4.2.Hematology
      • 5.1.6.4.3.Oncology
      • 5.1.6.4.4.Immunology
      • 5.1.6.4.5.Pulmonology
      • 5.1.6.4.6.Others
      • 5.1.6.5.By End-user
      • 5.1.6.5.1.Hospitals & Clinics
      • 5.1.6.5.2.Clinical Research
      • 5.1.6.5.3.Others
    • 5.1.7.Canada
    • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Product Type
  • 6.2.By Method
  • 6.3.By Application
  • 6.4.By End-user
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Patent Landscape
  • 9.2.Regulatory Approvals
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Grifols S.A.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.CSL Limited
  • 13.3.Takeda Pharmaceutical Company Limited
  • 13.4.Octapharma AG
  • 13.5.Kedrion S.p.A
  • 13.6.LFB S.A.
  • 13.7.Biotest AG
  • 13.8.Sanquin Innovation B.V.
  • 13.9.Bio Products Laboratory Ltd.
  • 13.10.Intas Pharmaceuticals Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 4.Global Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 5.Global Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 6.Global Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 7.Global Plasma Fractionation Market Share (%), By Region, 2017-2031F
  • Figure 8.North America Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 10.North America Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 11.North America Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 12.North America Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 13.North America Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 14.North America Plasma Fractionation Market Share (%), By Country, 2017-2031F
  • Figure 15.United States Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 17.United States Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 18.United States Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 19.United States Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 20.United States Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 21.Canada Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 23.Canada Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 24.Canada Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 25.Canada Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 26.Canada Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 27.Mexico Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 29.Mexico Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 30.Mexico Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 31.Mexico Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 32.Mexico Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 35.Europe Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 36.Europe Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 37.Europe Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 38.Europe Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 39.Europe Plasma Fractionation Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 42.Germany Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 43.Germany Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 44.Germany Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 45.Germany Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 46.France Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.France Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 49.France Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 50.France Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 51.France Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 52.Italy Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 54.Italy Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 55.Italy Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 56.Italy Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 57.Italy Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 58.United Kingdom Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 60.United Kingdom Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 61.United Kingdom Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 62.United Kingdom Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 63.United Kingdom Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 64.Russia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 66.Russia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 67.Russia Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 68.Russia Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 69.Russia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 70.Netherlands Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 72.Netherlands Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 73.Netherlands Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 74.Netherlands Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 75.Netherlands Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 76.Spain Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 78.Spain Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 79.Spain Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 80.Spain Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 81.Spain Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 82.Turkey Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 84.Turkey Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 85.Turkey Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 86.Turkey Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 87.Turkey Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 88.Poland Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Poland Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 91.Poland Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 92.Poland Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 93.Poland Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 94.South America Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 96.South America Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 97.South America Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 98.South America Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 99.South America Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 100.South America Plasma Fractionation Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 103.Brazil Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 104.Brazil Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 105.Brazil Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 106.Brazil Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 107.Argentina Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 109.Argentina Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 110.Argentina Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 111.Argentina Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 112.Argentina Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 113.Asia-Pacific Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 115.Asia-Pacific Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 116.Asia-Pacific Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 117.Asia-Pacific Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 118.Asia-Pacific Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 119.Asia-Pacific Plasma Fractionation Market Share (%), By Country, 2017-2031F
  • Figure 120.India Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 122.India Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 123.India Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 124.India Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 125.India Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 126.China Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 128.China Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 129.China Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 130.China Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 131.China Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 132.Japan Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 134.Japan Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 135.Japan Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 136.Japan Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 137.Japan Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 138.Australia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 140.Australia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 141.Australia Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 142.Australia Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 143.Australia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 144.Vietnam Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 146.Vietnam Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 147.Vietnam Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 148.Vietnam Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 149.Vietnam Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 150.South Korea Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 152.South Korea Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 153.South Korea Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 154.South Korea Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 155.South Korea Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 156.Indonesia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 158.Indonesia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 159.Indonesia Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 160.Indonesia Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 161.Indonesia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 162.Philippines Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 164.Philippines Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 165.Philippines Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 166.Philippines Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 167.Philippines Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 168.Middle East & Africa Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 170.Middle East & Africa Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 171.Middle East & Africa Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 172.Middle East & Africa Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 173.Middle East & Africa Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 174.Middle East & Africa Plasma Fractionation Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 177.Saudi Arabia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 178.Saudi Arabia Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 179.Saudi Arabia Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 180.Saudi Arabia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 181.UAE Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.UAE Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 184.UAE Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 185.UAE Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 186.UAE Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 187.South Africa Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
  • Figure 189.South Africa Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
  • Figure 190.South Africa Plasma Fractionation Market Share (%), By Method, 2017-2031F
  • Figure 191.South Africa Plasma Fractionation Market Share (%), By Application, 2017-2031F
  • Figure 192.South Africa Plasma Fractionation Market Share (%), By End-user, 2017-2031F
  • Figure 193.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Method Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023